OrthoPediatrics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

OrthoPediatrics şirketinin toplam hissedar öz sermayesi $370.9M ve toplam borcu $72.7M olup, bu da borç-öz sermaye oranını 19.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $489.3M ve $118.4M dir.

Anahtar bilgiler

19.6%

Borç/özkaynak oranı

US$72.67m

Borç

Faiz karşılama oranı	n/a
Nakit	US$76.06m
Eşitlik	US$370.92m
Toplam yükümlülükler	US$118.38m
Toplam varlıklar	US$489.29m

Son finansal sağlık güncellemeleri

OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?

May 07

Is OrthoPediatrics (NASDAQ:KIDS) Using Debt In A Risky Way?

Aug 08

Recent updates

Investors Still Waiting For A Pull Back In OrthoPediatrics Corp. (NASDAQ:KIDS)

Nov 05

The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 09

Shareholders Should Be Pleased With OrthoPediatrics Corp.'s (NASDAQ:KIDS) Price

Aug 02

OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets

May 09

OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?

May 07

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

Apr 10

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

Dec 20

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: KIDS 'nin kısa vadeli varlıkları ( $248.3M ) kısa vadeli yükümlülüklerini ( $34.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: KIDS şirketinin kısa vadeli varlıkları ( $248.3M ) uzun vadeli yükümlülüklerini ( $83.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: KIDS şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: KIDS 'nin borç/öz sermaye oranı son 5 yılda 59.5% seviyesinden 19.6% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: KIDS şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: KIDS serbest nakit akışı her yıl % 11.9 1.3 yıl yetecek nakit akışına sahip olacaktır.

OrthoPediatrics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?

Is OrthoPediatrics (NASDAQ:KIDS) Using Debt In A Risky Way?

Recent updates

OrthoPediatrics Corp. Increases Earnings Guidance for the Full Year 2024

Investors Still Waiting For A Pull Back In OrthoPediatrics Corp. (NASDAQ:KIDS)

OrthoPediatrics Corp. to Report Q3, 2024 Results on Nov 06, 2024

The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Orthopediatrics Corp. Reiterates Revenue Guidance for the Year 2024

Shareholders Should Be Pleased With OrthoPediatrics Corp.'s (NASDAQ:KIDS) Price

OrthoPediatrics Corp. to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Shareholder dilution

OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 7.5% to US$43.00

OrthoPediatrics Corp. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?

OrthoPediatrics Corp. Receives Breakthrough Device” Designation from FDA for eLLi Growing Rod System for Pediatric Patients with Scoliosis

OrthoPediatrics Corp. to Report Q1, 2024 Results on May 06, 2024

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

OrthoPediatrics Corp., Annual General Meeting, May 24, 2024

Consensus EPS estimates fall by 29%, revenue upgraded

President recently sold US$89k worth of stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Orthopediatrics Corp. Reiterates Revenue Guidance for Full Year 2024

Orthopediatrics Corp. Provides Revenue Guidance for Full Year 2024

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

Insider recently sold US$81k worth of stock

OrthoPediatrics Corp. to Report Q4, 2023 Results on Mar 06, 2024

OrthoPediatrics Corp. Provides Preliminary Unaudited Revenue Guidance Fourth Quarter and Full Year 2023 and for the Year 2024

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

OrthoPediatrics Corp. Reiterates Earnings Guidance for the Full Year of 2023

New minor risk - Profitability

Price target decreased by 16% to US$44.67

New minor risk - Shareholder dilution

OrthoPediatrics Corp. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.3% to US$50.00

OrthoPediatrics Corp. Launches DF2 Brace

OrthoPediatrics Corp. Reiterates Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OrthoPediatrics Corp. Announces the Launch and First Case Using the GIRO Growth Modulation System

Key Executive recently sold US$190k worth of stock

OrthoPediatrics Corp. Announces Election of George Dyer to its Board of Directors

OrthoPediatrics Corp. Announces Launch of Response Power Scoliosis System

Getting In Cheap On OrthoPediatrics Corp. (NASDAQ:KIDS) Might Be Difficult

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 21%

Insider recently sold US$112k worth of stock

Insider notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

OrthoPediatrics Corp. to Report Q4, 2022 Results on Feb 28, 2023

OrthoPediatrics Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 and Fiscal Year 2023

Less than half of directors are independent

OrthoPediatrics' (NASDAQ:KIDS) Earnings Aren't As Good As They Appear

Consensus forecasts updated

Price target decreased to US$57.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OrthoPediatrics Corp. Updates Revenue Guidance for the Year 2022

Less than half of directors are independent

Orthopediatrics Corp. Announces Retirement of Stephen F. Burns from Board of Directors

OrthoPediatrics Corp. to Report Q3, 2022 Results on Oct 31, 2022

OrthoPediatrics Corp. has completed a Follow-on Equity Offering in the amount of $125.124619 million.

Consensus estimates of losses per share improve by 13%

OrthoPediatrics announces public offering of stock, pre-funded warrants

Is OrthoPediatrics (NASDAQ:KIDS) Using Debt In A Risky Way?

Price target increased to US$63.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

OrthoPediatrics Corp. Revises Revenue Guidance for the Year 2022

OrthoPediatrics Corp. to Report Q2, 2022 Results on Aug 03, 2022

OrthoPediatrics enters distribution agreement with 3D-Side

OrthoPediatrics Corp. (NasdaqGM:KIDS) and OrthoPediatrics Canada ULC completed the acquisition of Pega Medical Inc. for CAD 33 million.

OrthoPediatrics Corp. announced that it has received $50 million in funding from Squadron Capital, LLC

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthopediatrics Corp. Provides Revenue Guidance for the Full Year 2022